Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus sham for VEGF-driven macular edema other than diabetic macular edema or retinal vein occlusion
NL-OMON40497Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in macular edema (2 arms), sponsored by Novartis. Primary endpoint: Best-corrected visual acuity change from baseline to Month 2. Started Apr 2014; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NL-OMON40497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40497.